

# Result of AGM

RNS Number : 4706K

Novacyt S.A.

30 June 2026

**Novacyt S.A.**

**("Novacyt", the "Company" or the "Group")**

## Result of AGM

**Paris, France, and Manchester, UK - 30 June 2026** - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the results of voting on the resolutions at its Annual General Meeting ('AGM'), held today, as set out in the Notice of AGM.

All Ordinary Resolutions presented at the Ordinary General Meeting were passed and Resolutions 11, 12, 15, 16, 21, 23, 24 and 25 were passed from the Extraordinary General Meeting. Full details of the results of the AGM voting are available on the Company's website.

An investor presentation by Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer, is now available on the Company's website and via the Investor Meet Company platform, with automated French subtitling <https://novacyt.com/investors/presentations/>

**Lyn Rees, CEO of Novacyt, said:** *"We would like to thank our shareholders for their continued support and for the approval of our key financial resolutions allowing the Group to be agile should inorganic opportunities present themselves and accelerate the process to achieve EBITDA profitability. Our focus remains on streamlining our operations and reducing our cost base enabling us to achieve sustainable long-term growth for our shareholders."*

## Contacts

Novacyt SA

<https://novacyt.com/investors>

---

Lyn Rees, Chief Executive Officer

Via Walbrook PR

Steve Gibson, Chief Financial Officer

**SP Angel Corporate Finance LLP (Nominated Adviser and Broker)** +44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)  
Vadim Alexandre / Rob Rees (Corporate Broking)

**Singer Capital Markets (Joint Broker)** +44 (0) 20 7496 3000

Phil Davies / James Fischer / Samed Ethem

**Allegra Finance (French Listing Sponsor)** +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com /  
Rémi Durgetto / Yannick Petit y.petit@allegrafinance.com

**Walbrook PR (Financial PR & IR)** +44 (0)20 7933 8780 or novacyt@walbrookpr.com  
Paul McManus / Lianne Applegarth +44 (0)7980 541 893 / +44 (0)7584 391 303  
Alice Woodings +44 (0)7407 804 654

**NOVACYT**  
GROUP

An international molecular diagnostics company,  
providing a broad portfolio of clinical and research  
use only products, and instrumentation

**PRIMER**  
DESIGN

 **Yourgene**  
Health

**SCD**  
SOUTHERN CROSS  
DIAGNOSTICS

**About Novacyt Group** ([www.novacyt.com](http://www.novacyt.com))

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

<b>Clinical</b>	<p>Broad portfolio of human clinical <i>in vitro</i> diagnostic products, workflows and services focused on three therapeutic areas:</p> <ul style="list-style-type: none"><li>· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests</li><li>· Precision Medicine: DPYD genotyping assay</li><li>· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel</li></ul>
<b>Instrumentation</b>	<p>Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:</p> <ul style="list-style-type: none"><li>· Ranger® Technology: automated DNA sample preparation and target enrichment technology</li><li>· genesig q16 and q32 real-time quantitative PCR (qPCR) instruments</li></ul>
<b>Research Use Only</b>	<p>Range of services for the life sciences industry:</p> <ul style="list-style-type: none"><li>· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry</li><li>· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)</li></ul>

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region.

The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com). RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGQBLFXQQLBBQ